Endocrine Abstracts

Abstract unavailable....

The treatment of osteoporosis consists of either antiresorptive or anabolic approaches. While there are a number of antiresorptive options available (i.e. bisphosphonates, SERMs and denosumab), teriparatide (PTH 1-34) is currently the only bone anabolic agent approved in the EU. The PTH-related protein (PTHrP) analogue abaloparatide and the sclerostin antibody romosozumab are two anabolic agents that are in the approval process for the treatment of postmenopausal osteoporosis....

Over past years various treatment options for osteoporosis have become available and withdrawn due to side effects or insufficient efficacy. This summary reviews sequential and combination therapy for osteoporosis with the currently approved first line treatments such as potent antiresorbtive (nitrogen-containing bisphosphonates (BP), denosumab (DM)) or anabolic agents (teriparatide, abaloparatide). We assume that all medications are taken with vitamin D and calcium supplement...